BMS-986489
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for BMS-986489, covering 2025-08-29 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). [Phase 3]